Chennai, Feb 23 (IANS) Vertically integrated pharma player Orchid Pharma Ltd said on Friday that it will launch its Enmetazobactam drug in the US in the next couple of quarters.
The company has received approval from the United States Food and Drug Administration (USFDA) for its invention Enmetaobactam, a Beta Lactamase Inhibitor.
The company shares went up to Rs 1,217.20 on Friday at the BSE after closing at Rs 1,150.95 on Thursday.
According to the company, the USFDA approval paves the way for the introduction of Enmetazobactam in the United States, the largest pharmaceutical market in the world.
The product is expected to be launched within the next couple of quarters in the US market.
This development comes in close succession to the recent recommendation for approval by the European Medicines Agency (EMA).
This New Drug Approval (NDA) allows the use of Exblifep (Cefepime and Enmetazobactam) as an injection for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI), including pyelonephritis caused by the following susceptible microorganisms — Escherichia coli (E. coli), Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, and Enterobacter cloacae complex.
“While the EMA recommendation for grant of marketing authorisation last month was a big achievement, the USFDA approval reinforces Orchid’s position on the safety of the drug and its innate need in the times of increasing Antimicrobial resistance,” said Manish Dhanuka, Managing Director, Orchid Pharma.
Enmetazobactam was invented in India by Orchid Pharma and then out licensed to Allecra Therapeutics for further development.
Dhanuka Group acquired Orchid Pharma through CIRP (Corporate Insolvency Resolution Process) under IBC (Insolvency and Bankruptcy Code) on March 31, 2020.
–IANS
vj/arm
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
